-
1
-
-
0032402278
-
Eisenmenger syndrome. Factors relating to deterioration and death
-
Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19:1845-55.
-
(1998)
Eur. Heart J.
, vol.19
, pp. 1845-1855
-
-
Daliento, L.1
Somerville, J.2
Presbitero, P.3
Menti, L.4
Brach-Prever, S.5
Rizzoli, G.6
-
2
-
-
0030041787
-
Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome
-
Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15:100-5.
-
(1996)
J. Heart Lung Transplant
, vol.15
, pp. 100-105
-
-
Hopkins, W.E.1
Ochoa, L.L.2
Richardson, G.W.3
Trulock, E.P.4
-
3
-
-
0033568143
-
Determinants of survival and length of survival in adults with Eisenmenger syndrome
-
Cantor WJ, Harrison DA, Moussadji JS, Connelly MS, Webb GD, Liu P, et al Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999; 84:677-81.
-
(1999)
Am. J. Cardiol.
, vol.84
, pp. 677-681
-
-
Cantor, W.J.1
Harrison, D.A.2
Moussadji, J.S.3
Connelly, M.S.4
Webb, G.D.5
Liu, P.6
-
4
-
-
0036238252
-
Poor prognosis and related factors in adults with Eisenmenger syndrome
-
Oya H, Nagaya N, Uematsu M, Satoh T, Sakamaki F, Kyotani S, et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J. 2002;143:739-44.
-
(2002)
Am. Heart J.
, vol.143
, pp. 739-744
-
-
Oya, H.1
Nagaya, N.2
Uematsu, M.3
Satoh, T.4
Sakamaki, F.5
Kyotani, S.6
-
5
-
-
0038306324
-
Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension
-
Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol. 2003;92:182-7.
-
(2003)
Am. J. Cardiol.
, vol.92
, pp. 182-187
-
-
Perloff, J.K.1
Hart, E.M.2
Greaves, S.M.3
Miner, P.D.4
Child, J.S.5
-
6
-
-
0035736488
-
Canadian Cardiovascular Society Consensus Conference 2001 update: Recommendations for the management of adults with congenital heart disease part III
-
Therrien J, Warnes C, Daliento L, Hess J, Hoffmann A, Marelli A, et al. Canadian Cardiovascular Society Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease part III. Can J Cardiol. 2001;17:1135-58.
-
(2001)
Can. J. Cardiol.
, vol.17
, pp. 1135-1158
-
-
Therrien, J.1
Warnes, C.2
Daliento, L.3
Hess, J.4
Hoffmann, A.5
Marelli, A.6
-
9
-
-
0022646182
-
Effect of long term oxygen treatment at home in children with pulmonary vascular disease
-
Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J. 1986;55:385-90.
-
(1986)
Br. Heart J.
, vol.55
, pp. 385-390
-
-
Bowyer, J.J.1
Busst, C.M.2
Denison, D.M.3
Shinebourne, E.A.4
-
10
-
-
16544367920
-
Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: A clinical dilemma
-
Broberg C, Ujita M, Babu-Narayan S, Rubens M, Prasad SK, Gibbs JS, et al. Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: a clinical dilemma. Heart. 2004;90:e63.
-
(2004)
Heart
, vol.90
-
-
Broberg, C.1
Ujita, M.2
Babu-Narayan, S.3
Rubens, M.4
Prasad, S.K.5
Gibbs, J.S.6
-
11
-
-
0026341605
-
Improvement of exercise capacity after nifedipine in patients with Eisenmenger syndrome complicating ventricular septal defect
-
Wong CK, Yeung DW, Lau CP, Cheng CH, Leung WH. Improvement of exercise capacity after nifedipine in patients with Eisenmenger syndrome complicating ventricular septal defect. Clin Cardiol. 1991;14:957-61.
-
(1991)
Clin. Cardiol.
, vol.14
, pp. 957-961
-
-
Wong, C.K.1
Yeung, D.W.2
Lau, C.P.3
Cheng, C.H.4
Leung, W.H.5
-
12
-
-
0026655377
-
Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children
-
Wimmer M, Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc Drugs Ther. 1992;6:183-6.
-
(1992)
Cardiovasc. Drugs Ther.
, vol.6
, pp. 183-186
-
-
Wimmer, M.1
Schlemmer, M.2
-
13
-
-
0034778877
-
Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome
-
Budts W, Van Pelt N, Gillyns H, Gewillig M, Van De Werf F, Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart. 2001;86:553-8.
-
(2001)
Heart
, vol.86
, pp. 553-558
-
-
Budts, W.1
Van Pelt, N.2
Gillyns, H.3
Gewillig, M.4
Van De Werf, F.5
Janssens, S.6
-
14
-
-
4444294201
-
Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension
-
Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25:1651-6.
-
(2004)
Eur. Heart J.
, vol.25
, pp. 1651-1656
-
-
Post, M.C.1
Janssens, S.2
Van de Werf, F.3
Budts, W.4
-
15
-
-
0042917870
-
Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease
-
Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108 Suppl 1:II167-73.
-
(2003)
Circulation
, vol.108
, Issue.SUPPL. 1
-
-
Schulze-Neick, I.1
Hartenstein, P.2
Li, J.3
Stiller, B.4
Nagdyman, N.5
Hubler, M.6
-
16
-
-
0030031888
-
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
-
The Primary Pulmonary Hypertension Study Group
-
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
-
(1996)
N. Engl. J. Med.
, vol.334
, pp. 296-302
-
-
Barst, R.J.1
Rubin, L.J.2
Long, W.A.3
McGoon, M.D.4
Rich, S.5
Badesch, D.B.6
-
17
-
-
0033551155
-
Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
-
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858-65.
-
(1999)
Circulation
, vol.99
, pp. 1858-1865
-
-
Rosenzweig, E.B.1
Kerstein, D.2
Barst, R.J.3
-
18
-
-
0036682273
-
Inhaled iloprost for severe pulmonary hypertension
-
Aerosolized Iloprost Randomized Study Group
-
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 322-329
-
-
Olschewski, H.1
Simonneau, G.2
Galie, N.3
Higenbottam, T.4
Naeije, R.5
Rubin, L.J.6
-
19
-
-
0026034713
-
Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
-
Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-9.
-
(1991)
Ann. Intern. Med.
, vol.114
, pp. 464-469
-
-
Stewart, D.J.1
Levy, R.D.2
Cernacek, P.3
Langleben, D.4
-
20
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
Galie, N.4
Black, C.M.5
Keogh, A.6
-
21
-
-
0037484589
-
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study
-
Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247-54.
-
(2003)
Chest
, vol.124
, pp. 247-254
-
-
Sitbon, O.1
Badesch, D.B.2
Channick, R.N.3
Frost, A.4
Robbins, I.M.5
Simonneau, G.6
-
22
-
-
12844272424
-
Safety and tolerability of bosentan in adults with Eisenmenger physiology
-
Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98:147-51.
-
(2005)
Int. J. Cardiol.
, vol.98
, pp. 147-151
-
-
Gatzoulis, M.A.1
Rogers, P.2
Li, W.3
Harries, C.4
Cramer, D.5
Ward, S.6
-
23
-
-
0036294907
-
Heart-lung or lung transplantation for Eisenmenger syndrome
-
Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant. 2002;21:731-7.
-
(2002)
J. Heart Lung Transplant
, vol.21
, pp. 731-737
-
-
Waddell, T.K.1
Bennett, L.2
Kennedy, R.3
Todd, T.R.4
Keshavjee, S.H.5
|